BPC-157 in 2026: what the evidence actually shows

BPC-157 has well over a hundred animal studies and only a handful of tiny human reports behind it. Here is what is known, what is not, and where it stands with the FDA and WADA.

BPC-157 may be the most talked-about peptide online. People call it a healing peptide for tendons, joints and the gut. In July 2026, an FDA advisory committee narrowly voted to recommend allowing pharmacies to compound it, which put it back in the news. This post sets out what the research actually supports.

What BPC-157 is

BPC-157 is a lab-made chain of 15 amino acids. Its sequence is taken from a larger protein first described in stomach juice. It was first written about in the scientific literature in 1993. It is not approved as a medicine in any country.

The animal evidence: a lot of it, all pointing the same way

Most BPC-157 research is in rats and other animals. Over three decades, studies have reported faster healing of injured tendons, ligaments, muscle, gut lining and other tissues. In its 2026 review, the FDA summarized animal studies in which BPC-157 prevented colon fistulas, liver damage and stomach lesions.

There are a few reasons to be careful with these results:

Results in rodents often fail to hold up in people.
Most of the research comes from one group at the University of Zagreb in Croatia, and independent groups have repeated relatively little of it.
The FDA noted that no one has worked out how the dose relates to the effect, and the molecule's targets in the body haven't been identified. Researchers have proposed explanations, such as more growth-factor signaling, new blood vessel growth and changes in nitric oxide. These remain theories.

A 2025 systematic review of BPC-157 in orthopaedic sports medicine, published in HSS Journal, found 36 relevant studies. Thirty-five were preclinical and only one was in humans.

The human evidence: a few small reports

When the FDA searched the medical literature for its July 2026 review, it found five clinical studies that used BPC-157:

Healthy volunteers, rectal enema: an early-2000s study in 24 people, reported only as a meeting abstract. The most common side effects listed were headache and flatulence.
Ulcerative colitis, enema: about 26 people on BPC-157 in a two-week trial, also known only from a meeting abstract. The FDA said the details were too thin to support either effectiveness or safety.
Knee pain (2021): a review of past patient charts from one Florida clinic. Of 12 people given a BPC-157 knee injection, 11 said their pain was much better when contacted by phone months later. There was no control group, no standard pain scale and no imaging.
Interstitial cystitis (2024): 12 women had BPC-157 injected into the bladder wall. The authors reported that most symptoms resolved. Again, there was no control group.
IV safety pilot (2025): two healthy adults, each of whom had used IV BPC-157 before, received 10 mg and then 20 mg. Blood tests showed no changes and they reported no side effects.

A registered phase 1 trial of an oral tablet (NCT02637284) planned to enroll 42 people, but it has posted no results, and the FDA could not find a published paper from it.

In total, that is a few dozen people, mostly in studies without placebo groups, and none longer than a few weeks of treatment. No large randomized controlled trial has been published. That is why we rate BPC-157 2 out of 5 for evidence.

Safety: mostly unknown

"No side effects reported" in a two-person study is not the same as "safe". The FDA's review concluded there is "insufficient clinical safety information to characterize the safety profile" of BPC-157. Its specific concerns included:

Immune reactions. As a 15-amino-acid peptide given by injection or nasal spray, BPC-157 "may pose a significant risk for immunogenicity". That risk could be higher if the product has impurities or the peptide has clumped together. No study has formally tested this.
Identity and purity. There is no official reference standard for BPC-157. The FDA said it is not well characterized chemically.
Long-term use. No human data covers repeated use over months.

The FDA's adverse-event database had three reports linked to injected BPC-157. They were an injection-site reaction, shortness of breath that led to an ER visit, and darkening of the skin and gums that came back when the person used the product again. That last product also contained TB-500 and was labeled "for research purposes only". These reports can't prove BPC-157 caused the problems.

There is also a theoretical concern. BPC-157 appears to encourage new blood vessel growth in lab studies, and some experts have asked whether that could matter for people with cancer. There is no human data either way.

Status with WADA

The World Anti-Doping Agency added BPC-157 to its Prohibited List in 2022, under section S0 (non-approved substances). It is banned at all times, in and out of competition. Because it isn't an approved medicine anywhere, athletes can't get a therapeutic use exemption for it.

Regulatory status in the US

Not FDA-approved for any use.
April 2026: removed from the FDA's Category 2 compounding list after its nominators withdrew the nomination. This did not make it legal to compound.
July 23, 2026: the Pharmacy Compounding Advisory Committee voted 8–6, with one abstention, to recommend adding it to the 503A bulks list for ulcerative colitis. The FDA's own staff had recommended against this.
Now: the vote is advisory. The FDA would still need to accept it and finish formal rulemaking before pharmacies could legally compound BPC-157. As of early October 2026, we have not found a proposed rule. Products sold online as "research chemicals" are unaffected and remain unregulated.

For more detail, see our separate post on the FDA's 2026 peptide compounding changes.

The bottom line

BPC-157's animal results are interesting and consistent. They are the kind of early findings that justify proper human trials, but those trials have not been done. Claims you see online about faster healing in people go well beyond what the evidence shows. Our BPC-157 page lists every known benefit and labels each one as human, animal, lab or anecdotal.

This is educational information, not medical advice.